SMS Lifesciences India Limited has informed regarding receipt of Establishment Inspection Report.
HALEOSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.8 pts more than Nifty Microcap 250 and 14.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SMS Lifesciences India has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its API manufacturing facility (Unit 1) at Kazipally, Telangana, with a Voluntary Action Indicated (VAI) classification. This follows the USFDA inspection that was earlier communicated on May 9, 2025. A VAI status means no critical compliance issues were found, though the company may need to take some voluntary corrective steps. The company stated that this outcome reaffirms its commitment to global quality standards and keeps the door open for supplying to the regulated U.S. market and other highly regulated global markets.
Positive for shareholders — clearance with VAI (rather than the more serious OAI classification) removes a key regulatory overhang and supports the company's ability to continue exports to the U.S. and other regulated markets, which is important for future revenue from the Kazipally Unit 1 facility.